Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Total raised: $16M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.08.2024 | Series A | $16M | - |
Mentions in press and media 3
| Date | Title | Description |
| 21.08.2024 | Business | Ambrosia Biosciences launches with $16M investment, Array chemistry team | Ambrosia Biosciences Inc., a recently formed drug-discovery company, has raised a $16 million Series A round and reunited a team of scientists that previously worked for Pfizer Inc.’s (NYSE: PFE) now-shuttered Boulder research and developme... |
| 20.08.2024 | Ambrosia Biosciences announces $16MM Series A Financing | Ambrosia Biosciences announces the closing of our Series A financing. Led by BVF Partners and Boulder Ventures, this funding will allow us to launch operations in Boulder, CO and fuel our exceptional drug discovery team. Initiates Small Mol... |
| - | Ambrosia Biosciences | “Ambrosia Biosciences” |